Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review.
ESC Heart Fail
; 10(4): 2718-2721, 2023 08.
Article
em En
| MEDLINE
| ID: mdl-37313579
ABSTRACT
Pulmonary arterial hypertension-targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48-year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO2 ), cTNI, and NT-proBNP changes indicated gradual recovery, without hepatic safety concerns. This case indicated that administering macitentan in patients diagnosed as PoPH (with CLF and HPS) may be efficient and safe enough in a clinical setting.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome Hepatopulmonar
/
Hipertensão Arterial Pulmonar
/
Hipertensão Portal
/
Hipertensão Pulmonar
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
ESC Heart Fail
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China